Throughline

Guidance ledger · Q4 FY26

Sun Pharmaceutical Industries Ltd SUNPHARMA

5 revisions on record · 1 lowered · 4 raised — the strikethrough is what management used to say

directional guidance only · shifted across quarters

Holding view → · latest concall · The pulse

↑ raised M&A strategy framing - tuck-in vs transformational Q3 FY26 → Q4 FY26
tuck-ins and smaller acquisitions for emerging markets, disciplined approach → Organon acquisition - same scale as Sun (~$6bn revenue), $11.75bn enterprise value, transformational
“this is a historic day in Sun journey as we”
↑ raised Balance sheet stance - net cash to leveraged Q3 FY26 → Q4 FY26
net cash of $3.2 billion at the consolidated level → net debt by EBITDA of 2.3x post-acquisition
“We also see that Sun from a net cash positive position post this acquisition will get into a net debt by EBITDA of”
↑ raised Cost synergy commitment from Organon Q3 FY26 → Q4 FY26
no synergy framework (no deal) → approximately $350 million estimated cost synergies in two-to-four years
“range of about $350 million which could be materialized in the next two to four years.”
↑ raised Biosimilars strategy posture Q3 FY26 → Q4 FY26
evaluating, re-looking at - including manufacturing, investment, overall cost of development → biosimilar becomes 6% of total revenues via Organon; will in-license further biosimilars pre-LOE
“Now coming to biosimilar which is a new platform for us. We are not present in biosimilar except few products”
↓ lowered Dividend policy continuity Q3 FY26 → Q4 FY26
interim dividend of Rs.11 per share for FY26 declared (Q3FY26) → deferred - 'We haven't fully reflected on this' post-acquisition
“The third important issue is, what it does to our dividend payments? We haven't fully reflected on this.”

Method. Revisions come from management's own stated numbers, compared quarter over quarter across the covered concalls; each carries the verbatim quote. “No revisions” can also mean guidance too vague to pin down — see the posture chip above. Not investment advice.